His innovative approaches and dedication to patient care have set new standards in treating obesity
Lipovive represents a higher upfront investment ranging from $79-294 depending on package selection, but provides professional formulation, quality assurance, and convenience that may justify higher costs for appropriate users
GLP-1 medications are changing how we think about treating obesity and metabolic disease, says Robert Kushner, MD, professor of medicine at Northwestern University and an obesity medicine specialist
Over the last few years, there has been near non-stop media and social media coverage of the "new weight loss drugs," GLP-1 receptor agonists such as semaglutide (Ozempic and Wegovy) and GLP-1 and GIP receptor agonist tirzepatide (Mounjaro and Zepbound)
Steven Batash, MD, is a board-certified gastroenterologist and leading physician at the Batash Endoscopic Weight Loss Center
GLP-1 Drugs Survey Report: What Employers Are and Arent Covering in 2026